Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science Startup Investors in United Kingdom

Last updated: Jul 2024 A list of 50 angel investors and VC funds that invest in Life science startups based in United kingdom. We rank investors based on the number of investments they made in Life science companies from United kingdom. We update this investor list every month.

Top 50 Life Science Startup Investors in United Kingdom

Investor	Life Science United Kingdom investments
Parkwalk Advisors	16
SOSV	13
Oxford Science Enterprises	12
UK Innovation & Science Seed Fund	12
Development Bank of Wales	8
24 Haymarket	7
Archangels	7
Jonathan Milner	7
GM&C Life Sciences Fund	7
Oxford Science Enterprises	7
Sofinnova Partners	6
Scottish Investment Bank	6
Selvedge Venture	6
Newable Private Investing	6
Angels in MedCity	6
Scottish Enterprise	5
Epidarex Capital	5
Deepbridge Capital	5
AlbionVC	4
O2h Ventures	4
Mercia Fund Managers	4
Angels 5K	4
Playfair Capital	4
11.2 Capital	4
IQ Capital	4
Nadav Rosenberg	4
Verve Ventures	4
Oxford Capital	4
SR One	4
Future Planet Capital	4
Formic Ventures	4
Syncona Partners LLP	4
Dementia Discovery Fund	4
R42 Group	3
Wren Capital	3
Bioeconomy Capital	3
Antler	3
Techstart Ventures	3
Calculus Capital	3
IP Group	3
Beltrae Partners	3
Fifty Years	3
Discovery Park	3
Kindred Capital	3
Martlet Capital	3
Hoxton Ventures	3
Octopus Ventures	3
Maven Capital Partners	3
Acequia Capital (AceCap)	3
Stefano Bernardi	3

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Psyomics — Technology to support better mental health assessment - accelerating patients to the right care pathway, first time.
Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
Cambridge Electric Cement — Cambridge Electric Cement is a sustainable cement start-up. Its breakthrough process co-recycles steel and cement to produce a low carbon, circular cement product that offers very low emissions[1], circular, and scalable alternative to existing cement production.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
OncoPrecision — We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity and Resistance Test, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access toPrecision Oncology and improve cancer patients' lives.
Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Funding Round
United Kingdom, United States, Finland

Portfolio highlights

Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Wave Photonics — Wave Photonics utilizes computational techniques to accelerate integrated photonics product designs.The company is developing a platform that provides optimized designs and streamlined integration between the supply chain using a software tool for predicting the performance and variation of a component for a given fabrication process and anoptimizer to generate a foundry-specific component library.Wave Photonics is headquartered in Bristol, Bristol.
Vector Photonics — Vector Photonics is a spin-out company from the University of Glasgow and is based in Glasgow, Scotland, one of the UK and world’s Optical and Photonics centres of excellence.
Presymptom Health — Presymptom Health is a pioneering medtech company that creates diagnostic tests to detect illnesses earlier to help save lives.

Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

Hope Macy — Hope Macy is a dynamic and expanding financial technology company. Its primary focus is on consumers who require additional security in managing their money, as well as those in the subprime sector.
Validient — Onboard Clients With Confidence - Automated Compliance Software, AML and due diligence solutions. Empower your business.
Peppercorn — Peppercorn is an insurance company that engages in auto insurance and financial services. The company uses technology to create smarter customer service experiences that give more control to customers, starting with car insurance. Peppercorn uses cutting-edge conversational AI to change the whole car insurance experience.

24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.

Investment focus

Health Care, Software, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

myGwork — The global recruitment & networking hub for LGBTQ+ professionals. Find jobs in lesbian, gay, bisexual and transgender friendly organisations. Grow your LGBTQ+ professional network. Read the latest LGBTQ+ professional news.
Previsico — Previsico is a spinOut company from Loughborough University specialising in modelling flooding in real-time, using weather predictions to make street-level flood nowcasts and forecasts. The company's mission is to be the leading global provider of cutting-edge flood prediction that saves lives and livelihoods.Its FloodMap Live producesround the clock street-level flood risk predictions and analytics. Uniquely, these are continuously modelled and updated using a combination of different weather forecasts. This allows the company to map the likelihood of short and long-term surface water events in real-time to the street level.
Huq Industries — The leading monitoring platform for footfall, dwell, catchment and traffic flows valued by government, retail and real-estate. Used by 50+ councils!

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
1inhaler — 1inhaler operates as a developer of drug delivery device.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United Kingdom, United States, Canada

Portfolio highlights

Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
Pencil Biosciences — Next Generation Genome Editing Tool
Relation Therapeutics — Relation uses machine learning to develop drugs for pressing unmet need.

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

Investment focus

Biotechnology, Health Care, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Cure51 — Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features and find new drugs to cure Cancer.
May Health — May Health is developing a modern treatment - Ovarian Rebalancing - designed to restore ovulation for people with polycystic ovary syndrome.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Speak with our Entrepreneurship Team, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.

Investment focus

Health Care, Biotechnology, Life Science
Seed, Pre-Seed, Series A
United Kingdom, Singapore

Portfolio highlights

Mesh Bio — Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks.
Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology

Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Angel
United Kingdom, United States

Portfolio highlights

Atelerix — Discover Atelerix's hypothermic hydrogels for eco-friendly, reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples today.
Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

Mirna — Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology.
Aurora Avionics — Accelerating launch-vehicle development with flexible and modular avionics platforms.
Vector Photonics — Vector Photonics is a spin-out company from the University of Glasgow and is based in Glasgow, Scotland, one of the UK and world’s Optical and Photonics centres of excellence.

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

Circada — Innovative Circadian lighting reconnects the body clock with nature
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which isauthorised and regulated by the Financial Conduct Authority.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Funding Round, Seed
United Kingdom, United States, France

Portfolio highlights

Mondra — AI-driven environmental insights platform that supports food system players to accelerate Scope 3 progress, reduce the cost of Net Zero, and drive competitive advantage.
Accelex — Accelex Technology, the technology solution to automate the acquisition, analysis and reporting of critical investment data. Learn more today.
OpenDialog AI — OpenDialog is the only conversational AI automation software to safely harness the most advanced Generative AI & LLMs in regulated sectors.

Focused on seeding early stage biotech therapeutics and related AI opportunities. The fund will invest in companies qualifying under EIS and covering novel...

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Pre-Seed
United Kingdom, Hungary

Portfolio highlights

Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
ViaNautis — Precision Solutions
Pencil Biosciences — Next Generation Genome Editing Tool

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Hungary

Portfolio highlights

Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
MGISS — Independently advising on the smarter use of Geospatial data, technology and the digital transformation of field operations.
Workbuzz — Give your Everyday Heroes a voice with employee engagement surveys. Our flexible and simple survey platform reaches all employees, wherever they are. Book a demo now!

Southern Angel Investors Club, combining Surrey investors Club & Angels 5K, are entrepreneurs who understand what new businesses need.

Investment focus

Biotechnology, Software, Medical
Seed, Funding Round, Angel
United Kingdom

Portfolio highlights

Celixir — Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchersto discover breakthrough medicines that aim to change the standard of medical care for patients.
Novastone Media — With its unique asymmetric technology, novastone puts you directly where your clients want to talk to you.
Geektastic — Geektastic guarantees hiring teams only meet high calibre candidates. Our technical code challenges quickly identify the most talented software engineers.

Playfair is a generalist VC fund with a contrarian approach to pre-seed technology investing. Based in London, Playfair invests across the UK and Europe with an intentionally high conviction, low volume approach: making 6-8 investments a year and preserving time, capital and resource to help companies post-investment. Playfair has backed 70+companies across two funds including Thought Machine, Andela, Mapillary, Recycleye and Orca AI.

Investment focus

Software, Artificial Intelligence, E-Commerce
Seed, Series A, Funding Round
United Kingdom, United States, France

Portfolio highlights

Orca AI — Orca AI innovates the marine navigation sphere, providing an intelligent technological solution for collision avoidance in maritime transport.
Nory AI — All of your restaurant operations managed in one platform, powered by AI. Tools that fuel better decision making and fatter profit margins.
Qureight — Pioneering data curation to solve complex diseases

In physics, 11.2 km/s is the escape velocity from Earth's gravity. They focus on emerging technologies such as AI, cybersecurity, robotics, quantum, new space, computational therapeutics, synthetic biology. They believe great people are leading indicators of a company's success. 11.2 Capital’s technical background, operationalexperience, and a strong network of amazing advisors and international partners particularly in Asia deliver a unique set of resources to entrepreneurs. While they are happy to help companies across the full range of early-stage company questions, areas where they concentrate include technical recruiting, partnerships (OEM and distribution partnerships for smart hardware companies, data partnerships for data-driven healthcare companies), customer introductions (CISO introductions for security companies, provider introductions for healthcare companies), and follow-on financings.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Series B
United States, Canada, United Kingdom

Portfolio highlights

Umedeor — Building consented patient cohorts that accelerate research and generate insights to improve outcomes for patients.
Thea Energy — Discover Thea Energy, a fusion energy company reinventing the stellarator to create a limitless source of zero emission energy for a sustainable future.
Coalesce Automation — Coalesce is the only data transformation tool built for scale. Evolve your transformations and empower your entire data team.

IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.

Investment focus

Software, Artificial Intelligence, Machine Learning
Seed, Series A, Funding Round
United Kingdom, United States, The Netherlands

Portfolio highlights

Baseimmune — Baseimmune data-driven vaccine design
Neurovalens — Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business.
Wobble Genomics — Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.

Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.

Investment focus

Biotechnology, Artificial Intelligence, Pharmaceutical
Seed, Pre-Seed, Series A
United Kingdom, Israel, Singapore

Portfolio highlights

thymia — Making mental health as objectively measurable as physical health.
Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
Loops — With Loops causal insights you can identify your biggest opportunities to maximize your KPIs... try the Loops way

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, Germany, France

Portfolio highlights

Axelera AI — A powerful, efficient, cost-effective, and user-friendly hardware and software AI platform to accelerate computer vision in edge devices.
Neustark ag — Neustark enables zero-emissions concrete by capturing concrete production emissions from the atmosphere and permanently converting them to limestone. This climate positive limestone replaces cement and sand which are major cost drivers for concrete production.
C12 Quantum Electronics — C12 Quantum Electronics develop reliable quantum processors with carbon nanotubes. Its unique technology reduces drastically the error rate, making the platform a prime candidate for noisy intermediate-scale quantum applications. The Paris, Ile-de-France, France-based company was formed in 2019 by Pierre and Matthieu Desjardins.

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Investment focus

Software, Health Care, Biotechnology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Ittybit — Ittybit is a API that enables users to handle rich media in applications. It provides developers with basic techniques for uploading, storing, transforming, and extracting data from video, music, and image files.
HealthKey — HealthKey is a platform that connects employers and insurers with health providers.
Noggin HQ — The next generation of credit referencing is coming. Look busy.

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Avalyn Pharma — This does NOT display on the home page
Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases

Brilliant Ideas. Brilliant People. Brilliant Minds.

Investment focus

Biotechnology, Health Care, Software
Funding Round, Seed, Convertible Note
United Kingdom, United States, Singapore

Portfolio highlights

Captura — Captura mission is globally scalable carbon capture to support a sustainable future for the climate.
You. Smart. Thing. — Our travel demand management platform generates personalised low-carbon travel plans that enhance visitor experience & increase revenues.
Armada Technologies — Armada Technologies created the world's first Passive Air Lubrication technology. This award-winning technology operates in a passive mode and allows for discrete control of system output while completely decoupling system lubrication from ship speed. In doing so, PALS can provide appropriate boundary layer aeration under every operatingstate.

Formic Ventures is a diversified venture capital firm that makes early-stage investments in biotechnology startups focused on human longevity as well as technology startups and companies that make human lives more meaningful.

Investment focus

Biotechnology, Health Care, Artificial Intelligence
Seed, Series A, Funding Round
United States, United Kingdom, Hong Kong

Portfolio highlights

Turn.bio — Turn Biotechnologies is a Stanford spinout developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered.Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation ofcellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells.
cheMastery — Laboratory Automation
Sampling Human — The mission of Sampling Human is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured.The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinicaldiagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine.The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS.

Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.

Investment focus

Biotechnology, Therapeutics, Medical
Series A, Series B, Seed
United Kingdom, United States, Switzerland

Portfolio highlights

Spur Therapeutics — Spur Therapeutics is a clinical-stage biotechnology business dedicated to creating life-changing medicines for crippling chronic illnesses.
SwanBio Therapeutics — SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions.
Yellowstone Biosciences — Yellowstone seeks to identify a novel class of frequently expressed antigens that can be therapeutically targeted, With the potential to dramatically improve patient outcomes.

SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
Sudo Biosciences — Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class.
Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.

R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.

Investment focus

Biotechnology, Health Care, Information Technology
Seed, Funding Round, Pre-Seed
United Kingdom, United States, Austria

Portfolio highlights

Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.
KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
Reservoir Neuroscience — Reservoir Neuroscience is a biopharma company that develops novel therapeutics to repair dysfunctional blood vessels in the brain. Reservoir Neuroscience was founded in 2019 and is based in Emeryville, California.

Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devicesto satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done.Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom

Portfolio highlights

Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
PharmEnable — At PharmEnable Therapeutics we access the inaccessible. We are re-imagining small molecule therapeutics through AI.
Bastion Therapeutics — Bastion Therapeutics - Enhancing Tregs To Restore Balance In Inflammatory Disorders Treg cell therapy for inflammatory disorders and autoimmune diseases.

Bioeconomy Capital invests in early-stage companies with the goal of accelerating the biotechnology revolution. Based on its startup operational expertise, product development experience, and globally recognized strategic analysis, it has developed a blueprint for building and deploying technological capabilities that will become a criticalinfrastructure of the 21st-century economy.The company's proprietary blueprint is the distillation of the fund managers' five decades of combined experience in synthetic biology and other engineering fields and cannot be readily duplicated. Prior investments include Zymergen, Riffyn, Synthace, RoosterBio, Arzeda, Bellwether Bio, EdenWorks, and Lumen Biosciences.

Investment focus

Biotechnology, Life Science, Pharmaceutical
Series A, Series B, Seed
United States, United Kingdom

Portfolio highlights

Arzeda — Arzeda develops enzyme design technology that presents a new way of thinking about biocatalysis. The company was founded by David Baker and three senior members of his lab to commercialize and further develop its computational enzyme design technology.
Tandem PV — Discover the future of sustainable energy with Tandem PV, a leader in perovskite solar technology and innovative solar energy solutions.
Parse Biosciences — Parse Biosciences is providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease. Learn more about how you can use the most scalable single cell platform on the market without the need for custom instrumentation.

Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!

Investment focus

Software, Information Technology, SaaS
Pre-Seed, Seed, Series A
Singapore, United Kingdom, Australia

Portfolio highlights

FitFlo — FitFlo brings to life the connected gym experience for Operators, Trainers and Members.
Mole — Mole is a digital business card and mobile website software. Connect with your clients, promote your business online and much more. Comes with free customised NFC business card.
Optacloud — Fostering a global AI powered ecosystem to achieve 100% cloud efficacy-> effortlessly, economically and eco-consciously. Dev tools stack for automating the entire development lifecycle of cloud apps across- Build, Deploy & Optimize.

Techstart Ventures is a leading investor of seed capital across Scotland and Northern Ireland. they are a trusted partner to ambitious founders on their journey to success.

Investment focus

Software, Information Technology, Health Care
Seed, Pre-Seed, Funding Round
United Kingdom, Ireland

Portfolio highlights

Saltroad — Get matched with an experienced HCPC Speech and Language Therapist based on your child's needs, your budget and your schedule. Loved by parents & children.
Sensoteq — We specialise in wireless sensor solutions for remote machine health monitoring. Sensoteq's technology enables predictive maintenance of industrial applications, preventing costly downtime and increasing efficiency.
Continuum Industries — Continuum Industries is a developer of Optioneer, the leading software for linear infrastructure optioneering.

At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Series A, Seed
United Kingdom, United States, Ireland

Portfolio highlights

WorkL — WorkL provides all the resources you need in one location to find employment, advance your career, connect with others, and communicate.
Tagomics — Tagomics transform disease diagnosis through comprehensive multitopic profiling.
MIP Discovery — MIP Diagnostics develop and manufacture molecularly imprinted polymers (nanoMIPs) that act as synthetic alternatives to antibodies for IVD and other industries.

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Investment focus

Health Care, Biotechnology, Therapeutics
Seed, Series A, Series B
United Kingdom, United States, Australia

Portfolio highlights

AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Independent Corporate Finance Advisors & Private Equity Investors

Investment focus

Health Care, Life Science, Biotechnology
Seed, Series A, Funding Round
United Kingdom

Portfolio highlights

Neurovalens — Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business.

WE BACK HEROES using technology to solve the world's biggest problems

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Germany, Canada

Portfolio highlights

Nabla Bio — Nabla is an autoreverse platform that enables the rapid discovery of previously unattainable protein variants with supernatural qualities. Nabla Bio makes new medicines and improve nutrition by engineering novel proteins.
The Bot Company — The Bot Company a household robot startup.
Molten Industries — Decarbonizing the world's chemical and heavy industries

Discovery Park is a thriving UK science park offering state-of-the-art lab space to rent and modern offices in Kent.

Investment focus

Life Science, Biotechnology, Biopharma
Pre-Seed, Seed
United Kingdom

Portfolio highlights

BugBiome — Reinventing Pest Control. Protecting People, Animals, and the Planet
BoobyBiome — BoobyBiome harnesses breast milk microbiome science to develop products to improve infant health

A new model for Venture Capital where every founder we back becomes a co-owner of the fund

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Series B
United Kingdom, Israel, Germany

Portfolio highlights

RobCo — Easily automate the repetitive tasks in your production facility with modular industrial robots from RobCo.
Cradle — Design better proteins
Sohar Health — Sohar Health is a platform for behavioral health companies. It is an API-based solution to handle eligibility verification, and AI-powered medical coding to automate manual workflows, increase patient intake, and generate more revenue

Martlet Capital is an early-stage investor based in Cambridge, providing patient capital to deep technology and life science startups with high growth potential. Investing in the future.

Investment focus

Biotechnology, Software, Health Care
Seed, Series A, Pre-Seed
United Kingdom, United States

Portfolio highlights

Xampla — Xampla: Drop-in replacements for single-use plastic, eliminating plastic pollution. Biodegrade quickly & safely. Named world's most promising cleantech co.
OctaiPipe — OctaiPipe safeguards critical infrastructure with AIoT devices, enhancing asset health and security while reducing cloud data transfers.
Infinitopes — Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives

Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.

Investment focus

Artificial Intelligence, Information Technology, Software
Seed, Series A, Funding Round
United Kingdom, United States, Canada

Portfolio highlights

Cogna — Cogna offers an AI-powered SaaS platform that streamlines the integration of data across several business domains.
Baseimmune — Baseimmune data-driven vaccine design
Fluent — Fluent empowers your decision makers with AI: ask data questions directly, get insights instantly.

We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.

Investment focus

Software, Health Care, FinTech
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
Infinitopes — Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives
ExpressionEdits — Redefining the status quo of protein expression

Maven is one of the UK's leading private equity and investment firms. We provide essential capital and expertise to help businesses unlock their potential.

Investment focus

Software, Information Technology, SaaS
Funding Round, Series A, Seed
United Kingdom, United States, Germany

Portfolio highlights

Carcinotech — Carcinotech has pioneered the development of assay-ready, 3D-bioprinted tumours derived from patient biopsies for oncology drug development.
Metrion Biosciences — Metrion Biosciences is a Contract Research Organization (CRO) that is located in the world renowned Cambridge biocluster.
McKenzie Intelligence Services Ltd — We deliver actionable intelligence on a global scale, empowering informed decision making for insurance and commercial clients across the world

We are a leading early-stage investment platform. We are at the center of a global ecosystem that attracts and fuels the technical founders and product teams building the next wave of global businesses.

Investment focus

Software, Information Technology, Artificial Intelligence
Seed, Series A, Pre-Seed
United States, United Kingdom, France

Portfolio highlights

Insempra — Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance.
Red Rover — We're on a mission to reimagine the multiplayer gaming landscape, with an emphasis on crafting groundbreaking survival experiences that champion player agency and drama.
ExpressionEdits — Redefining the status quo of protein expression

Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.

Investment focus

Software, Biotechnology, Artificial Intelligence
Seed, Pre-Seed, Funding Round
Italy, France, Norway

Portfolio highlights

Freatic — We bridge the gap between individuals with untapped knowledge and actors who can take advantage of these opportunities.
Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
CaSRevolution — A novel disease-modifying approach against neurodegeneration

Investors by industry

FinTech

Consumer

Gaming

Media (entertainment)

EdTech

Artificial intelligence